Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06872905 · ClinicalTrials.gov registry record
Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used in Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) to Treat Aortoiliac Occlusive Disease
A clinical trial of Aortoiliac Occlusive Disease, sponsored by W.L.Gore & Associates.
- Recruiting
- Registry status
- 158
- Enrollment target
- 18
- Study locations
NCT06872905: Recruiting study of Aortoiliac Occlusive Disease, sponsored by W.L.Gore & Associates.
NCT06872905 is a study of Aortoiliac Occlusive Disease that is actively recruiting participants, run by W.L.Gore & Associates. The registered enrollment target is 158 participants. The trial reports 18 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06872905, a study of Aortoiliac Occlusive Disease, is actively recruiting participants, sponsored by W.L.Gore & Associates.
- RECRUITING
- Registry status
- 158 participants
- Enrollment target
- 18
- Study locations
Study Summary
The study will assess the safety and effectiveness of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis ("VBX Device" or also referred to as "VBX Stent Graft") in a post approval setting and evaluate the quality of the use in covered endovascular reconstruction of the aortic bifurcation (CERAB) to treat Aortoiliac Occlusive Disease (AIOD).
Primary Outcome
Proportion of patients maintaining primary patency at 1 Year
Conditions Studied
Interventions
- DEVICE GORE VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX)
Study Locations (18)
Other
- Azienda Ospedaliero-Universitaria di Padova - Padua
- Ospedale di Circolo e Fondazione Macchi - Varese
- Amsterdam UMC Research BV - Amsterdam
- Franciscus - Rotterdam
- Hospital General Universitario de Alicante - Alicante
- Greater Glasgow Health Board - Glasgow
New Jersey
- Cooper University Hospital - Camden
- Rutgers - New Brunswick
New York
- Research Foundation SUNY Buffalo - Buffalo
- Mount Sinai Medical Center - New York
California
- University of California - Fresno
Minnesota
- Mayo Clinic Rochester - Rochester
Ohio
- Ohio State University Medical Center - Columbus
Pennsylvania
- University Of Pennsylvania - Philadelphia
Tennessee
- Wellmont Holston Valley Medical Center - Kingsport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2025-05-30 |
| Est. Completion | 2027-08-16 |
What NCT06872905 shows while recruiting
NCT06872905 is an observational study that tracks outcomes without assigning an intervention. The registered 158 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Aortoiliac Occlusive Disease appearing as the primary indexed condition, and to 1 intervention - of which GORE VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX) is the first listed.
NCT06872905 lists 18 locations in 11 states (Other, New Jersey, New York).
Frequently Asked Questions
What is clinical trial NCT06872905 about?
NCT06872905 is a clinical study titled "Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used in Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) to Treat Aortoiliac Occlusive Disease". The study will assess the safety and effectiveness of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis ("VBX Device" or also referred to as "VBX Stent Graft") in a post approval setting and evaluate the quality of the use in covered endovascular reconstruction of the aortic bifurcation (CERA...
What is the current status of trial NCT06872905?
This trial is currently recruiting. The enrollment target is 158 participants. The study started on 2025-05-30. Estimated completion is 2027-08-16.
What conditions does trial NCT06872905 study?
This clinical trial studies the following conditions: Aortoiliac Occlusive Disease.
What interventions are being tested in trial NCT06872905?
The interventions under investigation include: GORE VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX) (DEVICE).
Who is sponsoring clinical trial NCT06872905?
This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06872905 being conducted?
This trial has 18 study locations across California, Minnesota, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aortoiliac Occlusive Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Liposomal Bupivacaine/Bupivacaine in Rectus Sheath Blocks Versus Ropivacaine in Rectus Sheath Blocks And Catheters
RECRUITING · Phase 4
-
The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486833 · 158 participants · Phase 1
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
- NCT04697966 · 158 participants · NA
Mechanisms and Predictors of Change in App-Based Mindfulness Training for Adolescents
- NCT04969835 · 158 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
- NCT05230732 · 158 participants · NA
Neuromodulation of Inflammation and Endothelial Function
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI